DSDavid R. Sherman

David R. Sherman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


David R. Sherman has a total of 81 co-authors. Here are the top co-authors by number of shared publications:

  • Anuradha Kumar

    Seattle Biomedical Research Institute, Seattle, WA 98109, USA

    3 shared publications
  • Nitin S. Baliga

    Institute for Systems Biology Seattle Washington USA

    3 shared publications
  • David J. Reiss

    Institute for Systems Biology, 401 Terry Avenue North, Seattle, Washington 98109, USA

    2 shared publications
  • Jennifer M. Pang

    Seattle Biomedical Research Institute, Seattle, Washington, USA

    2 shared publications
  • Kyle J. Minch

    1] Seattle Biomedical Research Institute, Seattle, Washington 98109, USA [2] Interdisciplinary Program of Pathobiology, Department of Global Health, University of Washington, Seattle, Washington 98195, USA

    2 shared publications
  • Maurine D. Miner

    Affiliation Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America

    2 shared publications

Latest Publications

  • Identification of novel Mycobacterium tuberculosis CD4 T-cell antigens via high throughput proteome screening

    by Kaustuv Nayak, Lichen Jing, Ronnie M. Russell, D. Huw Davies, Gary Hermanson, Douglas M. Molina, Xiaowu Liang, David R. Sherman, William W. Kwok, Junbao Yang, et al.


  • Open Access

    A comprehensive map of genome-wide gene regulation in Mycobacterium tuberculosis

    by Serdar Turkarslan, Eliza J R Peterson, Tige R Rustad, Kyle J Minch, David J Reiss, Robert Morrison, Shuyi Ma, Nathan D Price, David R Sherman, Nitin S Baliga

    Mycobacterium tuberculosis (MTB) is a pathogenic bacterium responsible for 12 million active cases of tuberculosis (TB) worldwide. The complexity and critical regulatory components of MTB pathogenicity are still poorly understood despite extensive research efforts. In this study, we constructed the first systems-scale map of transcription factor (TF) binding sites and their regulatory target proteins in MTB. We constructed FLAG-tagged overexpression constructs for 206 TFs in MTB, used ChIP-seq to identify genome-wide binding events and surveyed global transcriptomic changes for each overexpressed TF. Here we present data for the most comprehensive map of MTB gene regulation to date. We also define elaborate quality control measures, extensive filtering steps, and the gene-level overlap between ChIP-seq and microarray datasets. Further, we describe the use of TF overexpression datasets to validate a global gene regulatory network model of MTB and describe an online source to explore the datasets.


  • Top Cited Papers
    Open Access

    The DNA-binding network of Mycobacterium tuberculosi s

    by Kyle J. Minch, Tige R. Rustad, Eliza J. R. Peterson, Jessica Winkler, David J. Reiss, Shuyi Ma, Mark Hickey, William Brabant, Bob Morrison, Serdar Turkarslan, et al.

    Mycobacterium tuberculosis (MTB) infects 30% of all humans and kills someone every 20–30 s. Here we report genome-wide binding for ~80% of all predicted MTB transcription factors (TFs), and assayed global expression following induction of each TF. The MTB DNA-binding network consists of ~16,000 binding events from 154 TFs. We identify >50 TF-DNA consensus motifs and >1,150 promoter-binding events directly associated with proximal gene regulation. An additional ~4,200 binding events are in promoter windows and represent strong candidates for direct transcriptional regulation under appropriate environmental conditions. However, we also identify >10,000 ‘dormant’ DNA-binding events that cannot be linked directly with proximal transcriptional control, suggesting that widespread DNA binding may be a common feature that should be considered when developing global models of coordinated gene expression.


  • Open Access

    Mycobacterium tuberculosis Strains Lacking Surface Lipid Phthiocerol Dimycocerosate Are Susceptible to Killing by an Early Innate Host Response

    by Tracey A. Day, John E. Mittler, Molly R. Nixon, Cullen Thompson, Maurine D. Miner, Mark J. Hickey, Reiling P. Liao, Jennifer M. Pang, Dmitry M. Shayakhmetov, David R. Sherman

    The innate immune response plays an important but unknown role in host defense against Mycobacterium tuberculosis . To define the function of innate immunity during tuberculosis, we evaluated M. tuberculosis replication dynamics during murine infection. Our data show that the early pulmonary innate immune response limits M. tuberculosis replication in a MyD88-dependent manner. Strikingly, we found that little M. tuberculosis cell death occurs during the first 2 weeks of infection. In contrast, M. tuberculosis cells deficient in the surface lipid phthiocerol dimycocerosate (PDIM) exhibited significant death rates, and consequently, total bacterial numbers were reduced. Host restriction of PDIM-deficient M. tuberculosis was not alleviated by the absence of interferon gamma (IFN-γ), inducible nitric oxide synthase (iNOS), or the phagocyte oxidase subunit p47. Taken together, these data indicate that PDIM protects M. tuberculosis from an early innate host response that is independent of IFN-γ, reactive nitrogen intermediates, and reactive oxygen species. By employing a pathogen replication tracking tool to evaluate M. tuberculosis replication and death during infection, we identify both host and pathogen factors affecting the outcome of infection.


  • Folate Pathway Disruption Leads to Critical Disruption of Methionine Derivatives in Mycobacterium tuberculosis

    by Molly R. Nixon, Kurt W. Saionz, Mi-Sun Koo, Michael J. Szymonifka, Hunmin Jung, Justin P. Roberts, Madhumita Nandakumar, Anuradha Kumar, Reiling Liao, Tige Rustad, et al.


  • Open Access

    A High-Throughput Screen against Pantothenate Synthetase (PanC) Identifies 3-Biphenyl-4-Cyanopyrrole-2-Carboxylic Acids as a New Class of Inhibitor with Activity against Mycobacterium tuberculosis

    by Anuradha Kumar, Allen Casey, Joshua Odingo, Edward A. Kesicki, Garth Abrahams, Michal Vieth, Thierry Masquelin, Valerie Mizrahi, Philip A. Hipskind, David R. Sherman, et al.

    The enzyme pantothenate synthetase, PanC, is an attractive drug target in Mycobacterium tuberculosis. It is essential for the in vitro growth of M. tuberculosis and for survival of the bacteria in the mouse model of infection. PanC is absent from mammals. We developed an enzyme-based assay to identify inhibitors of PanC, optimized it for high-throughput screening, and tested a large and diverse library of compounds for activity. Two compounds belonging to the same chemical class of 3-biphenyl-4- cyanopyrrole-2-carboxylic acids had activity against the purified recombinant protein, and also inhibited growth of live M. tuberculosis in manner consistent with PanC inhibition. Thus we have identified a new class of PanC inhibitors with whole cell activity that can be further developed.


  • Open Access

    Global analysis of mRNA stability in Mycobacterium tuberculosis

    by Tige R. Rustad, Kyle J. Minch, William Brabant, Jessica K. Winkler, David J. Reiss, Nitin S. Baliga, David R. Sherman

    Mycobacterium tuberculosis (MTB) is a highly successful pathogen that infects over a billion people. As with most organisms, MTB adapts to stress by modifying its transcriptional profile. Remodeling of the transcriptome requires both altering the transcription rate and clearing away the existing mRNA through degradation, a process that can be directly regulated in response to stress. To understand better how MTB adapts to the harsh environs of the human host, we performed a global survey of the decay rates of MTB mRNA transcripts. Decay rates were measured for 2139 of the ∼4000 MTB genes, which displayed an average half-life of 9.5 min. This is nearly twice the average mRNA half-life of other prokaryotic organisms where these measurements have been made. The transcriptome was further stabilized in response to lowered temperature and hypoxic stress. The generally stable transcriptome described here, and the additional stabilization in response to physiologically relevant stresses, has far-ranging implications for how this pathogen is able to adapt in its human host.


  • Open Access

    High-throughput Screening and Sensitized Bacteria Identify an M. tuberculosis Dihydrofolate Reductase Inhibitor with Whole Cell Activity

    by Anuradha Kumar, Meng Zhang, Linyun Zhu, Reiling P. Liao, Charles Mutai, Shittu Hafsat, David R. Sherman, Ming-Wei Wang

    Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis, is a bacterial pathogen that claims roughly 1.4 million lives every year. Current drug regimens are inefficient at clearing infection, requiring at least 6 months of chemotherapy, and resistance to existing agents is rising. There is an urgent need for new drugs that are more effective and faster acting. The folate pathway has been successfully targeted in other pathogens and diseases, but has not yielded a lead drug against tuberculosis. We developed a high-throughput screening assay against Mtb dihydrofolate reductase (DHFR), a critical enzyme in the folate pathway, and screened a library consisting of 32,000 synthetic and natural product-derived compounds. One potent inhibitor containing a quinazoline ring was identified. This compound was active against the wild-type laboratory strain H37Rv (MIC99 = 207 µM). In addition, an Mtb strain with artificially lowered DHFR levels showed increased sensitivity to this compound (MIC99 = 70.7 µM), supporting that the inhibition was target-specific. Our results demonstrate the potential to identify Mtb DHFR inhibitors with activity against whole cells, and indicate the power of using a recombinant strain of Mtb expressing lower levels of DHFR to facilitate the discovery of antimycobacterial agents. With these new tools, we highlight the folate pathway as a potential target for new drugs to combat the tuberculosis epidemic.


  • Open Access

    Mycobacterium tuberculosis Growth following Aerobic Expression of the DosR Regulon

    by Kyle Minch, Tige Rustad, David R. Sherman

    The Mycobacterium tuberculosis regulator DosR is induced by multiple stimuli including hypoxia, nitric oxide and redox stress. Overlap of these stimuli with conditions thought to promote latency in infected patients fuels a model in which DosR regulon expression is correlated with bacteriostasis in vitro and a proxy for latency in vivo. Here, we find that inducing the DosR regulon to wildtype levels in aerobic, replicating M. tuberculosis does not alter bacterial growth kinetics. We conclude that DosR regulon expression alone is insufficient for bacterial latency, but rather is expressed during a range of growth states in a dynamic environment.


  • The Polyketide Pks1 Contributes to Biofilm Formation in Mycobacterium tuberculosis

    by Jennifer M. Pang, Emilie Layre, Lindsay Sweet, Ashley Sherrid, D. Branch Moody, Anil Ojha, David R. Sherman

    Infections caused by biofilms are abundant and highly persistent, displaying phenotypic resistance to high concentrations of antimicrobials and modulating host immune systems. Tuberculosis (TB), caused by Mycobacterium tuberculosis , shares these qualities with biofilm infections. To identify genetic determinants of biofilm formation in M. tuberculosis , we performed a small-scale transposon screen using an in vitro pellicle biofilm assay. We identified five M. tuberculosis mutants that were reproducibly attenuated for biofilm production relative to that of the parent strain H37Rv. One of the most attenuated mutants is interrupted in pks1 , a polyketide synthase gene. When fused with pks15 , as in some M. tuberculosis isolates, pks1 contributes to synthesis of the immunomodulatory phenolic glycolipids (PGLs). However, in strains such as H37Rv with split pks15 and pks1 loci, PGL is not produced and pks1 has no previously defined role. We showed that pks1 complementation restores biofilm production independently of the known role of pks1 in PGL synthesis. We also assessed the relationship among biofilm formation, the pks15/1 genotype, and M. tuberculosis phylogeography. A global survey of M. tuberculosis clinical isolates revealed surprising sequence variability in the pks15/1 locus and substantial variation in biofilm phenotypes. Our studies identify novel M. tuberculosis genes that contribute to biofilm production, including pks1 . In addition, we find that the ability to make pellicle biofilms is common among M. tuberculosis isolates from throughout the world, suggesting that this trait is relevant to TB propagation or persistence.